-
Something wrong with this record ?
Population pharmacokinetics-pharmacodynamics of fondaparinux in dialysis-dependent chronic kidney disease patients undergoing chronic renal replacement therapy
D. Michaličková, JM. Hartinger, Z. Hladinová, V. Bednářová, B. Szonowská, V. Polakovič, A. Matthios, V. Tesař, O. Slanař, EHJ. Krekels
Language English Country Germany
Document type Journal Article, Observational Study
Grant support
Project Progres Q25
Univerzita Karlova v Praze
No. SVV 260 523
Univerzita Karlova v Praze
NLK
ProQuest Central
from 1997-01-01 to 1 year ago
CINAHL Plus with Full Text (EBSCOhost)
from 2008-01-01 to 1 year ago
Medline Complete (EBSCOhost)
from 2000-01-01 to 1 year ago
Nursing & Allied Health Database (ProQuest)
from 1997-01-01 to 1 year ago
Health & Medicine (ProQuest)
from 1997-01-01 to 1 year ago
- MeSH
- Renal Insufficiency, Chronic metabolism therapy MeSH
- Fondaparinux pharmacokinetics pharmacology MeSH
- Factor Xa Inhibitors pharmacokinetics pharmacology MeSH
- Middle Aged MeSH
- Humans MeSH
- Renal Replacement Therapy * MeSH
- Retrospective Studies MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Body Weight MeSH
- Age Factors MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Observational Study MeSH
PURPOSE: Data on the anti-Xa efficacy of fondaparinux in dialysis-dependent chronic kidney disease (DD-CKD) patients are scarce. This study characterizes the pharmacokinetics (PK) and pharmacodynamics (PD) of fondaparinux in DD-CKD patients undergoing renal replacement therapy (RRT), to assess dosing strategies. METHODS: A retrospective, observational study was conducted using data on anti-Xa activity (112 samples) from 12 (3 male and 9 female) DD-CKD patients (median (IQR) age 71 years (63-88), weight 73 kg (59-98.5)). Eleven patients underwent high-flux or low-flux hemodialysis (HD) and one patient underwent peritoneal dialysis. Three patients were also treated with therapeutic plasma exchange (TPE). A non-linear mixed effects analysis was performed using NONMEM 7.3.0. RESULTS: The lab-specific slope of the relationship between fondaparinux concentration and anti-Xa levels was 1.18 IU/μg. In a one-compartment model, clearance (CL) and volume of distribution (Vd) were 0.05289 L/h and 5.55 L, respectively. High-flux HD was found to increase the CL of fondaparinux 2.26 times. TPE also considerably increased CL, but the fold-change could not be accurately estimated. Low-flux HD and peritoneal dialysis did not impact PK parameters. CONCLUSIONS: Model-based simulations showed that standard dosing (2.5 mg three times weekly before HD) results in a median anti-Xa activity of 0.55 IU/mL and 0.98 IU/mL, pre- and post-low-flux HD, respectively. In patients undergoing high-flux HD, these values are approximately 27% lower. Additional caution is warranted with TPE, as this treatment can reduce anti-Xa activity even further.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22011462
- 003
- CZ-PrNML
- 005
- 20240522101957.0
- 007
- ta
- 008
- 220425s2022 gw f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s00228-021-03201-1 $2 doi
- 035 __
- $a (PubMed)34414464
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Michaličková, Danica $u Institute of Pharmacology, First Faculty of Medicine & General University Hospital, Charles University, Prague, Czech Republic. marrtta@gmail.com $1 https://orcid.org/0000000296909846
- 245 10
- $a Population pharmacokinetics-pharmacodynamics of fondaparinux in dialysis-dependent chronic kidney disease patients undergoing chronic renal replacement therapy / $c D. Michaličková, JM. Hartinger, Z. Hladinová, V. Bednářová, B. Szonowská, V. Polakovič, A. Matthios, V. Tesař, O. Slanař, EHJ. Krekels
- 520 9_
- $a PURPOSE: Data on the anti-Xa efficacy of fondaparinux in dialysis-dependent chronic kidney disease (DD-CKD) patients are scarce. This study characterizes the pharmacokinetics (PK) and pharmacodynamics (PD) of fondaparinux in DD-CKD patients undergoing renal replacement therapy (RRT), to assess dosing strategies. METHODS: A retrospective, observational study was conducted using data on anti-Xa activity (112 samples) from 12 (3 male and 9 female) DD-CKD patients (median (IQR) age 71 years (63-88), weight 73 kg (59-98.5)). Eleven patients underwent high-flux or low-flux hemodialysis (HD) and one patient underwent peritoneal dialysis. Three patients were also treated with therapeutic plasma exchange (TPE). A non-linear mixed effects analysis was performed using NONMEM 7.3.0. RESULTS: The lab-specific slope of the relationship between fondaparinux concentration and anti-Xa levels was 1.18 IU/μg. In a one-compartment model, clearance (CL) and volume of distribution (Vd) were 0.05289 L/h and 5.55 L, respectively. High-flux HD was found to increase the CL of fondaparinux 2.26 times. TPE also considerably increased CL, but the fold-change could not be accurately estimated. Low-flux HD and peritoneal dialysis did not impact PK parameters. CONCLUSIONS: Model-based simulations showed that standard dosing (2.5 mg three times weekly before HD) results in a median anti-Xa activity of 0.55 IU/mL and 0.98 IU/mL, pre- and post-low-flux HD, respectively. In patients undergoing high-flux HD, these values are approximately 27% lower. Additional caution is warranted with TPE, as this treatment can reduce anti-Xa activity even further.
- 650 _2
- $a věkové faktory $7 D000367
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a tělesná hmotnost $7 D001835
- 650 _2
- $a inhibitory faktoru Xa $x farmakokinetika $x farmakologie $7 D065427
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a fondaparinux $x farmakokinetika $x farmakologie $7 D000077425
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a chronická renální insuficience $x metabolismus $x terapie $7 D051436
- 650 12
- $a náhrada funkce ledvin $7 D017582
- 650 _2
- $a retrospektivní studie $7 D012189
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a pozorovací studie $7 D064888
- 700 1_
- $a Hartinger, Jan $u Institute of Pharmacology, First Faculty of Medicine & General University Hospital, Charles University, Prague, Czech Republic $7 xx0224709
- 700 1_
- $a Hladinová, Zuzana $u Department of Nephrology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic
- 700 1_
- $a Bednářová, Vladimíra $u Department of Nephrology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic
- 700 1_
- $a Szonowská, Barbora $u Internal Department of Strahov, General University Hospital, Prague, Czech Republic
- 700 1_
- $a Polakovič, Vladimír $u Internal Department of Strahov, General University Hospital, Prague, Czech Republic
- 700 1_
- $a Matthios, Andreas $u Institute of Pharmacology, First Faculty of Medicine & General University Hospital, Charles University, Prague, Czech Republic $u Department of Biophysics and Physical Chemistry, Faculty of Pharmacy, Charles University, Hradec Králové, Czech Republic
- 700 1_
- $a Tesař, Vladimír $u Department of Nephrology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic
- 700 1_
- $a Slanař, Ondřej $u Institute of Pharmacology, First Faculty of Medicine & General University Hospital, Charles University, Prague, Czech Republic
- 700 1_
- $a Krekels, Elke H J $u Division of Systems Biomedicine and Pharmacology, Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands
- 773 0_
- $w MED00001613 $t European journal of clinical pharmacology $x 1432-1041 $g Roč. 78, č. 1 (2022), s. 89-98
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34414464 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220425 $b ABA008
- 991 __
- $a 20240522101952 $b ABA008
- 999 __
- $a ok $b bmc $g 1789186 $s 1162660
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 78 $c 1 $d 89-98 $e 20210819 $i 1432-1041 $m European journal of clinical pharmacology $n Eur J Clin Pharmacol $x MED00001613
- GRA __
- $a Project Progres Q25 $p Univerzita Karlova v Praze
- GRA __
- $a No. SVV 260 523 $p Univerzita Karlova v Praze
- LZP __
- $a Pubmed-20220425
